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Trypanosomatid-caused conditions (African trypanosomiasis, Chagas disease,
and leishmaniasis) are neglected tropical infectious diseases that mainly affect
socioeconomically vulnerable populations. The available therapeutics display substantial
limitations, among them limited efficacy, safety issues, drug resistance, and, in some
cases, inconvenient routes of administration, which made the scenarios with insufficient
health infrastructure settings inconvenient. Pharmaceutical nanocarriers may provide
solutions to some of these obstacles, improving the efficacy–safety balance and
tolerability to therapeutic interventions. Here, we overview the state of the art of
therapeutics for trypanosomatid-caused diseases (including approved drugs and
drugs undergoing clinical trials) and the literature on nanolipid pharmaceutical carriers
encapsulating approved and non-approved drugs for these diseases. Numerous
studies have focused on the obtention and preclinical assessment of lipid nanocarriers,
particularly those addressing the two currently most challenging trypanosomatid-caused
diseases, Chagas disease, and leishmaniasis. In general, in vitro and in vivo studies
suggest that delivering the drugs using such type of nanocarriers could improve
the efficacy–safety balance, diminishing cytotoxicity and organ toxicity, especially in
leishmaniasis. This constitutes a very relevant outcome, as it opens the possibility to
extended treatment regimens and improved compliance. Despite these advances,
last-generation nanosystems, such as targeted nanocarriers and hybrid systems, have
still not been extensively explored in the field of trypanosomatid-caused conditions
and represent promising opportunities for future developments. The potential use of
nanotechnology in extended, well-tolerated drug regimens is particularly interesting
in the light of recent descriptions of quiescent/dormant stages of Leishmania and
Trypanosoma cruzi, which have been linked to therapeutic failure.
Keywords: Chagas, leishmaniasis, human African trypanosomiasis, lipid nanoparticles, liposomes, solid lipid nano
particles, nanoestructed lipid carrier, nanoparticle
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INTRODUCTION
Since the first description of liposomes in the mid-1960s, lipid-
based pharmaceutical nanocarriers have made their way to the
market and have undergone substantial evolution (Puri et al.,
2009; Akbarzadeh et al., 2013). Their applications in the medical
field include drug delivery, imaging molecules, decoration
with ligands for site-specific targeting, and formulation with
destabilizing lipid systems that allow for on-demand drug release.
A relevant parameter of an ideal drug vehicle is the absence of
toxicity (both for the patient and the environment) of the carrier
itself or its by-products. Among the wide array of nanomaterials,
lipid-based systems are undoubtedly among the safest ones (Puri
et al., 2009). Later generations of lipid-based drug delivery
systems include solid lipid nanoparticle (SLN), nanostructured-
lipid carriers (NLCs), and, more recently, lipid–polymer hybrid
systems (Puri et al., 2009; Mukherjee et al., 2019; Liu et al., 2020)
and quatsomes (Ferrer-Tasies et al., 2013). It is expected that
such drug carriers will allow for higher control over drug release,
enhanced stability, and increased circulation times. Some general
advantages of lipid nanosystems are schematically summarized in
Figure 1.
Trypanosomatid-caused human conditions, namely, Chagas
disease, leishmaniasis, and human African trypanosomiasis
(HAT), are considered as neglected infectious diseases that
have been listed as high-priority diseases by the World Health
Organization (WHO), needing innovative and increased disease
management (Parthasarathy and Kalesh, 2020). The real amount
of infected people is possibly miscalculated as available figures
are often extrapolation of data from incomplete epidemiological
surveys. Also, the situation worsened by social and military
conflicts and because of undiagnosed or unreported patients
living in rural areas with limited access to health system facilities
FIGURE 1 | General advantages of lipid-based nanosystems.
(Malvy and Chappuis, 2011). In 2010, it was estimated that
these conditions affected about 27 million people worldwide
and caused ∼150,000 annual deaths (Nussbaum et al., 2010).
Since then, depending on the case, advance and retreats have
been registered. For instance, a 90% drop in the number
of African trypanosomiasis cases has been realized between
2009 and 2018 (World Health Organization, 2020a), and
the first all-oral medication for such condition has recently
been launched (Deeks, 2019). On the other hand, a jump
of 26.9% in leishmaniasis prevalence was observed between
2006 and 2016 (GBD 2016 Disease Injury Incidence Prevalence
Collaborators, 2017). As no vaccine is available, treatment
solely depends on chemotherapy. Specifically, in the case of
Chagas disease and leishmaniasis, available treatment options
are dramatically limited. Among disadvantages of much of
the available therapeutic arsenal, we might mention toxicity,
emerging drug-resistance issues, high costs, limited efficacy, and
inconvenient routes of administration (Patterson and Wyllie,
2014). Therefore, novel therapeutic options are urgently required
to improve both accessibility and therapeutic output and
control potential resistance issues. Interestingly, the existence
of quiescent and dormant stages (characterized by low or
no replication and diminished metabolic activity) has been
described, respectively, in Leishmania and Trypanosoma cruzi
(Berg et al., 2013; Kloehn et al., 2015; Jara et al., 2017, 2019;
Sánchez-Valdez et al., 2018). Depending on the case, such forms
may emerge spontaneously (Sánchez-Valdez et al., 2018) or as an
adaptive response to stress conditions (e.g., drug pressure) (Berg
et al., 2013; Jara et al., 2019), contributing to treatment failure. It
has been suggested that these new resistance mechanisms, which
add to classical genetic-based drug resistance, may be treated
using current drugs in extended therapeutic regimens that extend
beyond the dormancy potential (Sánchez-Valdez et al., 2018).
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Here, we will briefly overview the trypanosomatid-caused
human diseases, along with the strengths and limitations
known chemotherapies to treat such conditions and recent or
ongoing clinical trials. Later, we will review the recent advances
on lipid nanocarriers encapsulating available and potential
pharmacological agents against Chagas disease, sleeping sickness,
and leishmaniasis. Noteworthy, other types of nanomaterials
(e.g., polymeric systems and metal nanoparticles) have also
been investigated (see, for instance, Ahmad et al., 2020; Nafari
et al., 2020), although they fall outside the scope of the present
review and article collection. Finally, some concluding remarks
including possible future directions in the field will be included.
Other recent reviews on the topic have been published,
including a comprehensive review on drug nanocarriers of
different materials targeting trypanosomatid-caused diseases
(Volpedo et al., 2019) and reviews exclusively focused on a given
condition (Quezada et al., 2019; Saleem et al., 2019) or in specific
drugs encapsulated in a diversity of nanocarriers (Arrúa et al.,
2019).
LITERATURE SURVEY
We initially search in Scopus all the combinations of one
of the following terms “Chagas disease,” “leishmaniasis,”
“human African trypanosomiasis,” “Trypanosoma cruzi,”
“Trypanosoma brucei,” “Leishmania” with one of the following
terms “nanocarrier,” “nanolipid,” “solid lipid nanoparticles,”
“nanostructured lipid carrier,” “nanosystem,” “drug delivery.”
Two of the authors (GM and MLS) scrutinized the abstracts of
the resulting articles and selected those related to the review
scope. The search was conducted in Google Scholar and Scopus.
HUMAN AFRICAN TRYPANOSOMIASIS
HAT is transmitted by the tsetse fly Glossina spp.; the etiologic
agents are two subspecies of Trypanosoma brucei (World
Health Organization, 2020a). The disease presents a first stage
(also called hemolymphatic, or early stage), taking place when
the parasite invades the bloodstream, and a second stage
(meningoencephalitic, or late stage) linked to invasion of the
patient’s central nervous system (CNS) by the parasite. In
humans, the disease presents in two forms, depending on
the parasite subspecies involved. When the etiological agent
is T. brucei gambiense (gHAT), the disease usually evolves
without major signs or symptoms. Nevertheless, when symptoms
emerge, the patient has often reached the advanced stage of
the disease, compromising the CNS and narrowing treatment
options. On the other hand, when the infection is caused by
T. brucei rhodesiense (rHAT), the disease develops rapidly, with
the first signs/symptoms being observed as soon as a few weeks
after infection, also compromising the CNS (World Health
Organization, 2020a).
Human African Trypanosomiasis Treatment
Today, WHO recommends a diversity of treatment options
against HAT, depending on the parasite subspecies involved
and the evolution stage of the disease, including pentamidine,
suramin, melarsoprol, eflornithine, nifurtimox, and fexinidazole.
Pentamidine appeared in 1940 and has since then been
employed for the treatment of the early phase of gHAT. It is an
aromatic diamidine that has numerous undesirable side effects
such as disturbances of glucose homeostasis, leukopenia, and
hypotension, as well as an inconvenient route of administration
(intramuscular) (Yang et al., 2014; Sbaraglini et al., 2016). Besides,
it has low brain–blood barrier (BBB) permeability, which means
that is not effective for the treatment of late-stage HAT.
Suramin reached the market in 1920 and is still one of the
treatment options for the first stage of rHAT. Its most frequent
side effect is urticarial rash (which affects around 90% of the
patients). Other adverse events include reversible nephrotoxicity,
pyrexia, and nausea (Nagle et al., 2014).
For the treatment of second stage of HAT, an arsenic derivate
has been recommended for years: the melarsoprol. It was
employed from 1949 (Nok, 2003), but its toxicity is extremely
high, causing severe encephalopathic syndrome in some cases,
which is associated to high mortality rate (Kennedy, 2004).
Another approved drug for the treatment of HAT is
eflornithine, a repurposed drug first explored as anticancer agent
(Nwaka and Hudson, 2006). Eflornithine has been used as an
alternative to melarsoprol, and its mode of action involves
the inhibition of the enzyme ornithine decarboxylase (O’Shea
et al., 2016). Its side effects are less severe than those of
melarsoprol, but it requires intravenous administration because
of its low oral bioavailability. This is an important drawback
if one considers that most patients with HAT have limited
access to adequate health facilities, complicating the follow-
up. Furthermore, it is active only against T. b. gambiense.
The outcome is significantly improved when eflornithine is
combined with nifurtimox. As monotherapy in T. b. gambiense
infections, nifurtimox is effective against both the early and
late stages, but it has a very variable cure rate (30–80%)
and high toxicity upon long-term administration (Bouteille
et al., 2003). Nifurtimox combined with eflornithine (Nagle
et al., 2014), though, is an interesting therapeutic choice, and
it was incorporated to the WHO List of Essential Medicines
for the treatment of gHAT (World Health Organization,
2020a).
In 1983, Raether and Seidenath reported fexinidazole
as a highly active new antiparasitic drug effective against
trichomonads, Entamoeba histolytica and T. cruzi, but the
project was abandoned by the pharmaceutical company Hoechst
when its tropical disease program was shut down (Raether
and Seidenath, 1983). Thanks to the non-profit Drugs for
Neglected Diseases initiative (DNDi) organization and the
pharmaceutical company Sanofi joint efforts, this drug finalized
preclinical stage and underwent clinical trials (Fairlamb, 2019).
It has been approved as the first all oral medication against
both hemolymphatic and meningoenchepalitic gHAT, and it
is undergoing a 5-year clinical trial to prove its efficacy
against rHAT (ClinicalTrials.gov NCT03974178, 2020; Drugs for
Neglected Diseases initiative, 2020e). After oral administration,
fexinidazole is readily distributed throughout the body, including
the brain (Tarral et al., 2014).





































TABLE 1 | Drugs approved or under clinical trials for the treatment of human African trypanosomiasis (HAT).
Drugs Stage of the disease Administration via Adverse reactions References
WHO-recommended drug treatments
Pentamidine
First stage Intramuscular Hyperglycemia or hypoglycemia, prolongation of the QT




First stage Intravenous Renal failure, skin lesions, anaphylactic shock, bone




Second Stage Intravenous Reactive arsenical encephalopathy (RAE) has been
attributed to the toxic effect of melarsoprol, peripheral
neuropathy, cutaneous reactions, renal or hepatic
dysfunction, allergic or hypersensitivity reactions
(Nok, 2003; Eperon et al., 2014)
Eflornithine
Second stage. Only useful
against T. b. gambiense
Intravenous Generally, are reversible after the end of treatment.
Convulsions, gastrointestinal symptoms such as nausea,
vomiting, and diarrhea; bone marrow toxicity leading to
anemia, leukopenia, and thrombocytopenia
(Burri, 2010; Alirol et al., 2013)
Nifurtimox & Eflornithine First and second stage Intravenous (eflornithine)
Oral (nifurtimox)
Convulsions, gastrointestinal symptoms such as nausea,
vomiting, and diarrhea; Genotoxicity, neurotoxicity
(Burri, 2010; Yun et al., 2010;
Kuemmerle et al., 2020)
Fexinidazole
First and second stage of T.
b. gambiense infection






























































































































































































































































































































































































) Currently, the oxaborole SCYX-7158 is undergoing clinical
trials for the treatment of HAT. Encouraging results of SCYX-
7158 in animal models made the responsible researchers
suspect that it might be a good treatment option for
late-stage HAT (Jacobs et al., 2011). Two other oxaborole
compounds, SCYX-1608210 and SCYX-1330682, have shown
good performance in animal models of the disease (Drugs
for Neglected Diseases initiative, 2020c). In 2015, a placebo-
controlled, randomized, double-blind study was completed,
which assessed the tolerability and pharmacokinetic parameters
of SCYX-7158 (ClinicalTrials.gov NCT01533961, 2020). The
study confirmed that the drug readily crosses the BBB, thus being
a promising candidate to treat late-stage HAT, although some
adverse effects such as gastrointestinal reactions and headaches
were observed (Drugs for Neglected Diseases initiative, 2020c).
Based on these results, a phase II/III trial started in 2017,
to evaluate the effectiveness and safety of SCYX-7158 as an
oral treatment for adult patients with gHAT (ClinicalTrials.gov
NCT03087955, 2020). The chosen dosage regimen involved a
single administration of 960mg. Phase II/III results are awaited
in the next years (Dickie et al., 2020).
Table 1 summarizes the therapeutic scenario for HAT.
Lipid Nanosystems Encapsulating
Approved Drugs
Limited permeability across the blood–brain barrier by
therapeutic agents is one of the main limitations that an
efficacious trypanocidal agent may present to be considered a
valid option to treat late-stage HAT. For instance, pentamidine
is mostly ineffective once the parasite has invaded the CNS,
and such lack of efficacy is thought to respond to its inability
to enter the brain. The limited bioavailability of pentamidine
in the brain has been demonstrated in mice by Sanderson
et al. (2009), whose results suggested that the drug distribution
to the brain is conditioned by active efflux mediated by P-
glycoprotein and multidrug resistance–associated proteins.
Different approaches have been used for the delivery of drugs
to the brain, such as intracerebroventricular administration
or intranasal delivery. Among them, vector-mediated brain
delivery, involving enhanced brain bioavailability through
drug-carrier conjugates, seems particularly promising because
of its versatility and reduced side effects compared to other
delivery options (Li et al., 2017; Gondim et al., 2019). Omarch
et al. (2019) investigated the permeability of polycaprolactone
nanoparticles and liposomes containing both pentamidine
across a monolayer of immortalized mouse brain endothelioma
cells. Pentamidine-loaded polycaprolactone nanoparticles
showed a mean diameter of 267.6 nm and zeta potential
of −28.1mV, whereas liposomes had a mean diameter of
119.6 nm and zeta potential of 11.78. Both systems displayed low
dispersity and similar loading capacity. After 24 h, liposomes and
polycaprolactone nanoparticles transported 87 and 66% of the
doses, respectively. Besides, free pentamidine penetration was
only 63% of the dose. The data suggested that lipid structures
can be promising nanocarriers to increase brain bioavailability
of pentamidine.
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Lipid Nanosystems Encapsulating
Non-approved Drugs
Like pentamidine, diminazene aceturate is a trypanocidal
aromatic diamidine of veterinary use. Its mode of action
involves the irreversible inhibition of S-adenosyl-L-methionine
decarboxylase of the trypanosome (Pépin and Milord, 1994). In
the past, diminazene aceturate has been used off-label by national
control programs and clinicians in many HAT endemic regions
of the world, with the consequent ethical controversy (Pépin and
Milord, 1994). Diminazene presents limited stability and brain
bioavailability (Kroubi et al., 2010).
Kroubi et al. (2010) obtained cationic polysaccharide
nanoparticles with a lipid core (anionic phospholipids). It
was previously observed that these types of nanocarrier could
be endocytosed by the blood–brain barrier endothelial cells
and did not activate the complement system, which strongly
suggests a stealth behavior (Jallouli et al., 2007; Paillard et al.,
2010). The authors tested two drug loading approaches, in
process (at 80◦C) and post-loading (at room temperature),
although poor stability was observed in the former approach.
The hydrodynamic diameter of the prepared nanoparticles was
74 nm, with low dispersion and a zeta potential+29mV. Possibly
because of the porous nature of the nanosystem, the mean
size was not changed by the drug load. The loading capacity
and stability of the hybrid nanoparticles greatly depended on
the drug to phospholipid ratio: formulations with a drug-
to-phospholipid ratio <5% were stable in terms of size,
charge, and drug loading for at least 6 months (4◦C). It was
also observed that the encapsulation of the drug protected
it against oxidation, being stable for at least 6 months at
4◦C. Furthermore, in vitro assays on T. brucei showed an




Chagas disease, caused by the protozoan T. cruzi, is endemic to
Latin America, but it has also spread to non-endemic countries
because of human migration. It is transmitted mainly through
an insect vector commonly known as “kissing bug” or vinchuca
(Triatoma infestans), but other transmission ways have become
increasingly relevant, including congenital transmission, blood
transfusion, and organ transplant (Pereira and Navarro, 2013;
World Health Organization, 2020b). It presents itself in two or
three stages (acute and chronic, or acute, latent/undetermined,
and chronic), depending on bibliographic sources. The acute
stage is associated with a high parasite load in blood and
displays absent or mild and unspecific symptoms. In the chronic
stage, the parasite predominates in other tissues (mainly in
the heart and digestive muscles), with up to 30% of patients
experiencing cardiac disease and around 10% displaying digestive
complications. The chronic stage often leads to sudden death
due to cardiac cardiomyopathy (World Health Organization,
2020b).
Chagas Disease Treatment
Only two trypanocidal drugs are available to treat Chagas
disease: benznidazole and nifurtimox, with both being discovered
around 1970 (World Health Organization, 2020a). The mode
of action of benznidazole involves the covalent modification of
biomolecules, due to the generation of reactive intermediates
emerging from reduction of the nitro group (Mecca et al.,
2008). It is highly efficacious in the acute stage; however, as
the disease progresses, the efficacy decreases, and the cure
rate in the chronic phase is estimated around 10–20% (Prata,
2001). The BENEFIT was a multicenter, prospective, randomized
study including patients with Chagas’ cardiomyopathy who
received benznidazole or placebo for up to an 80-day period
(Morillo et al., 2015). Two thousand eight hundred fifty-four
patients were followed up for more than 5 years after the
intervention. Sixty-six percent of the patients treated with
benznidazole reverted positive polymerase chain reaction (PCR)
results in comparison to 33.5% of patients in the placebo
arm. This positive outcome, nonetheless, was overshadowed by
the fact that cardiac deterioration was not prevented in the
active arm. It is worth mentioning that benznidazole is often
poorly tolerated, presenting adverse reactions/side effects such as
rashes, peripheral neuropathy, hypersensitivity syndromes with
fever, lymphadenopathy, exfoliative dermatitis, anorexia, nausea,
vomiting, and insomnia (World Health Organization, 2020a),
which often lead to treatment interruption.
Nifurtimox, the second-line treatment, is prescribed in cases
where benznidazole is not well-tolerated. Its mode of action,
again, relates to the reduction of the nitro group, leading to
the formation of reactive oxygen species (Urbina and Docampo,
2003, Maya et al., 2007). As previously discussed, nifurtimox
is also associated to several complications, including anorexia,
psychic disorders, irritability, insomnia, nausea, and diarrhea
(Bern et al., 2007).
Regarding recent and ongoing clinical trials, disappointing
results were obtained with the repurposed antifungal
posaconazole. Docampo et al. (1981) were the first to suggest the
use of azole compounds against T. cruzi. In 2010, posaconazole
was included in a clinical trial to assess its efficacy against
chronic Chagas disease. It did show trypanosomal activity,
but more posaconazole patients (compared with benznidazole
treatment) showed failure throughout the follow-up of the
treatment (Molina et al., 2014; ClinicalTrials.gov NCT01162967,
2020). Later, a second trial was started to study the efficacy of
oral posaconazole for the treatment of asymptomatic Chagas
disease (ClinicalTrials.gov NCT01377480, 2020), but once
again, the investigators found better performance in the control
arm (Morillo et al., 2017). Highly sensitive bioluminescence
studies were later performed with bioluminescent T. cruzi to
assess parasite survival in mice, after treatment with either
posaconazole or benznidazole; cyclophosphamide-induced
immunosuppression was used to facilitate the detection of
relapse (Fortes Francisco et al., 2015). While 20-day treatment
with benznidazole was successful to achieve sterile cure,
posaconazole failed in almost all cases. In the acute phase, the
adipose tissue appears to be the major reservoir of recurrence in
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mice under posaconazole therapy. Inadequate choice of the dose
at clinical trials and emergence of azole-resistant parasites should
also be considered as possible explanations to the failure at the
clinical studies (Campos et al., 2017; Villalta and Rachakonda,
2019).
E-1224 (a prodrug of ravuconazole) is another azole being
investigated as potential therapy for Chagas (Diniz et al., 2018).
In 2011, a proof-of-concept study was started in individuals
with chronic indeterminate Chagas disease (ClinicalTrials.gov
NCT01489228, 2020) but the outcome did not cover the
expectations, as the control group showed better results after 1-
year treatment (Torrico et al., 2018). More recent studies are
focusing on the evaluation of improved treatment regimens of
benznidazole in monotherapy and in combination with E1224
(ClinicalTrials.gov NCT03378661, 2020).
After Bahia et al. (2012) demonstrated the in vitro an in
vivo effects over T cruzi, fexinidazole entered a phase II trial
to determine its efficacy in adults with chronic indeterminate
disease, finding that the drug was highly effective at the
lowest dose (ClinicalTrials.gov NCT02498782, 2020; Drugs for
Neglected Diseases initiative, 2020j). A second study started a
few years later in which 3, 7, and 10 days of treatment with low
doses of the drugs are being evaluated, to establish the minimal
effective and safe dose to treat adult patients undergoing chronic
indeterminate Chagas disease (ClinicalTrials.gov NCT03587766,
2020). Results are expected in 2020.
A second study started a few years later for adult patients’
therapy having chronic indeterminate Chagas sickness for which
they received 3, 7, and 10 days of treatment with low drug doses.
As cardiac deterioration is the major complication in chronic
Chagas disease, there are also some undergoing trials focused
on ameliorating Chagas cardiomyopathy. In 2009, a clinical
trial started to estimate the effect of selenium treatment on
prevention of heart disease progression in cardiac patients with
Chagas (ClinicalTrials.gov NCT00875173, 2020). Selenium has
preventedmyocardial lesions in acute and chronic models (Souza
et al., 2010). In 2018, there were protocol modifications (Holanda
et al., 2018), and recruitment of patients has been reestablished.
Results should be expected soon, and if the hypothesis of the trial
is confirmed, the inclusion of this micronutrient in the daily diet
could have a therapeutic effect on Chagas myocardiopathy.
Another example of a repurposed drug that could be used
to treat the Chagas-associated cardiomyopathy is the antigout
agent colchicine, which has demonstrated cardioprotective
effects (reduced fibrosis and diminished inflammation in the
cardiac tissue) (Fernandes et al., 2012). Positive effects on
myocardial remodeling, linked to interference in the synthesis
of collagen, were also reported. Currently, a clinical study is in
the recruiting phase, with the first results being expected by 2021
(ClinicalTrials.gov NCT03704181, 2020).
Finally, amiodarone is a class III antiarrhythmic agent
and was first found as an antimycotic (Courchesne, 2002;
Hejchman et al., 2012). Later, Benaim et al. (2006) reported
its trypanocidal effects against T. cruzi (Bellera et al., 2013).
The potential benefits on both its cardiovascular activity and
the intracellular Ca2+ regulation of the parasite make this
compound particularly attractive. An ongoing phase III clinical
trial (ATTACH) was designed to test the effect of amiodarone,
administered over 6 months, in subjects with mild to moderate
Chagas cardiomyopathy; secondarily, potential trypanocidal
effects associated with beneficial clinical effects will be explored
(ClinicalTrials.gov NCT03193749, 2020).
Table 2 presents a summary of the therapeutic scenario for
Chagas disease, including approved drugs and drugs that have or
are undergoing clinical trials.
Lipid Nanosystems Encapsulating
Approved Drugs
Although much of the efforts toward encapsulation of
benznidazole and nifurtimox has focused on polymeric
nanosystems, a considerable number of studies have also
been published reporting the use of lipid-based nanocarriers,
especially in the case of the first-line therapy benznidazole (Arrúa
et al., 2019).
Morilla et al. (2002) reported the obtention of benznidazole
multilamellar liposomal formulations; they proposed that such
strategy would compensate benznidazole low solubility and
improve its biodistribution. Among many tested formulations,
the highest drug load was observed in hydrogenated
phosphatidylcholine from soybean: cholesterol: distearoyl-
phosphatidylglycerol in a molar ratio of 2:2:1. Drug loading
of 2 g of the drug per 100 g of lipids was achieved. A 450-fold
dilution in buffer at 37◦C led to a reduction in the quantity of
drug associated to liposomes from 2 g to 0.25 g/100 g of total
lipids at 65% of drug lost per minute since the first minute
and by severe decrease of drug release (0.4% of drug lost per
minute) in the next hour. The low efficiency of the drug carrier
concomitantly with high amount of drug loss can be attributed
to the liposomal thermodynamic instability under physiological
conditions (Cacicedo et al., 2016). Subsequently, the same
authors investigated the ability of such liposomes to enhance
the delivery of benznidazole to the liver in rats (Morilla et al.,
2004). Three-fold raise in benznidazole was accumulated in the
liver, together with 1.1µg/mL BNZ in blood, which is 30% lower
than the blood BNZ concentration achieved upon intravenous
administration of free drug happened 4 h post-ijnjection. Besides,
the increase of BNZ liver uptake had no effect on parasitemia
levels of mice infected with the RA T. cruzi strain.
A diversity of nanocarriers encapsulating benznidazole
(among them, several lipid-based systems) were studied by
the BERENICE consortium (BEnznidazol and triazol REsearch
group for Nanomedicine and Innovation on Chagas disease,
a project originally conceived to develop low-cost therapeutic
interventions for Chagas disease using nanotechnology to
reduce the final dose of the drug) (Vinuesa et al., 2017). The
drug delivery systems tested included different cyclodextrins,
quatsomes, liposomes, SLN, and NLC formulations. Liposomal
formulations sedimented in time, although this behavior was
prevented through PEGylation. The release profiles of the SLN
and NLC showed a considerable initial burst release. In the
case of SLN, those with the higher benznidazole load (20%)
released 18% of the load at 1.5 h. Subsequently, the release rate
was much slower (the maximum drug release was 19.5%). The





































TABLE 2 | Summary of the therapeutic scenario for Chagas disease, including WHO-recommended therapies, and recent/undergoing clinical trials.
Drugs Stage of the disease Administration
via
Adverse reactions References
Drugs used to treat Chagas disease recommended by WHO
Benznidazole
First line of treatment
Acute phase
Chronic phase
Oral Rashes, peripheral neuropathy, hypersensitivity syndromes with
fever, lymphadenopathy, exfoliative dermatitis, anorexia, nausea,
vomiting, weight loss, and insomnia
(Bern et al., 2007; Mecca et al., 2008;




(for those patients who do
not tolerate benznidazole)
Oral Anorexia, weight loss, psychic disorders, irritability, insomnia,
nausea, diarrhea
(Urbina and Docampo, 2003; Bern et al., 2007;
Maya et al., 2007; Boiani et al., 2010; Hall et al.,




Oral Drug interactions related to CYP3A4 inhibition. Caution must be
taken when coadministered with other CYP3A4 substrates. Care
must be taken when administered to a patient with arrhythmic
disorders or taking proarrhythmic drugs
(Molina et al., 2014; Morillo et al., 2017; Urbina,
2017; ClinicalTrials.gov NCT01377480, 2020;
Echeverría et al., 2020)
Fexinidazole Acute phase
Chronic phase


























































































TABLE 2 | Continued
Drugs Stage of the disease Administration
via
Adverse reactions References




Ravuconazole E-1224 Chronic phase
Selenium For prevent Chagas
cardiomyopathy
Oral Not reported (Holanda et al., 2018; ClinicalTrials.gov
NCT00875173, 2020)
Colchicine For prevent Chagas
cardiomyopathy
Oral Not reported (ClinicalTrials.gov NCT03704181, 2020)
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maximum release achieved with the NLC was higher than that
of SLN (up to 55% of the load for the highest drug load, i.e.,
30%), and the initial burst was reached only 5 h later. Regarding
cytotoxicity of the empty carriers, quatsomes resulted to be highly
cytotoxic at high concentrations. Liposomal preparations were
much less cytotoxic, with some of them displaying negligible
toxicity. NLC showed dose-dependent (but low) cytotoxicity:
empty NLC showed at most 10% toxicity (at 100 µg/mL)
on mice fibroblasts. A paradoxical (unexplained) behavior was
registered, since the higher the benznidazole load, the smaller
the toxicity detected. Similarly, CD had low cytotoxicity. None
of the formulations tested provided substantial improvement on
the trypanocidal effect of benznidazole, and only cyclodextrin
complexes achieved some improvement in the selectivity index.
These discouraging results possibly led the BERENICE team to
discard the nanotechnology approach.
Another recent study investigated the ability of oil-in-
water nanoemulsions to modify benznidazole release and
their impact on the parasite viability (Streck et al., 2019).
Dispersions of medium-chain triglycerides were stabilized by
using phosphatidylcholine and sodium oleate. The nanoemulsion
increased benznidazole apparent aqueous solubility and led
to a slower drug release. Cell viability studies revealed
that the nanoformulation enhanced the cytotoxicity at high
concentrations (200 µg mL−1). The tested formulations also
induced a remarkable increment of efficacy against epimastigotes
and trypomastigotes, in comparison with the free drug.
Lipid Nanosystems Encapsulating
Non-approved Drugs
In 1999, the performance of three marketed lipid amphotericin
B formulations (i.e., the liposomal AmBisomeTM, the lipid
complex AbelcettTM, and AmphocilTM, a colloidal dispersion)
was challenged in vitro and in vivo against amphotericin B
deoxycholate (FungizoneTM). Amphocil and Fungizone showed
42- and 7-fold more activity than Abelcet and AmBisome against
amastigotes of T. cruzi in macrophages, respectively. However,
the tested formulations showed similar performance against
T. cruzi amastigotes in cultures of Vero cells. Interestingly,
administration of a single 25 mg/kg dose of AmBisome inhibited
acute infections of T. cruzi in mice, whereas at the same
dose the other lipid formulations enhanced the survival rate,
but the infections were not eliminated in all animals (Yardley
and Croft, 1999). These results clearly evidence the absence
of in vitro–in vivo correlation. In good agreement with these
findings, Cencig et al. (2011) proved that the increase in
survival and parasitemia decreases in the course of acute or
chronic phases of T. cruzi of infected mice by six intraperitoneal
AmBisome injections. Analysis by quantitative PCR of infected
mice showed significant parasite load reductions in heart,
spleen, skeletal muscle, liver, and adipose tissues in both
phases. Noteworthy, earlier administration of the amphotericin
B formulation led to increased efficacy in parasite load decreases
in spleen and liver, and recurrent drug administration also
had beneficial effects in the parasite load in heart and liver
during the chronic phase. Unfortunately, immunosuppression
with cyclophosphamide boosted the infection to parasite levels
equivalent to untreated animals acutely infected. These results
strongly suggest that, at least in the assayed dosing schedule, the
liposomal formulation failed to fully cure the infection.
Morilla et al. (2005) encapsulated the trypanocidal drug
etanidazole in pH-sensitive liposomes made of dioleoyl-
phosphatidylethanolamine and cholesteryl hemisuccinate 6:4.
The liposomes were also loaded with a fluorescent probe. Their
mean diameter was around 380 nm. The mean size drastically
changed (5-fold increase) when the pH of the external media
dropped from 8.7 to 3 (it would have been interesting, though,
to study the behavior at intermediate, physiologically relevant
pH values). It was demonstrated that they were phagocytosed
by uninfected and T. cruzi–infected macrophages, eliciting an
appreciable trypanocidal effect, while control with free drug did
not show any therapeutic effect. Intravenous administration of
the encapsulated drug to infectedmice also decreased parasitemia
levels, whereas administration of a 180-fold higher dose of the
free drug had no positive effect.
Carneiro et al. (2014) developed SLN containing the
potential trypanocidal drug lead 5-hydroxy-3-methyl-5-phenyl-
pyrazoline-1-(S-benzyldithiocarbazate). The mean diameter of
the loaded SLNwas 127 nmwith low dispersity; the zeta potential
revealed a considerably negative surface charge (−56.1mV). A
high entrapment efficiency was also demonstrated. The in vitro
and in vivo performances of the encapsulated drug, the free drug,
and benznidazole were compared. The SLN system outperformed
the other treatments in a mice model of infection, both in terms
of parasitemia reduction. Liver inflammation and damage were
also diminished by the drug-loaded nanocarrier.
More recently, Spósito et al. (2017) resorted to a self-
emulsifying formulation to efficiently deliver ravuconazole,
a low-solubility drug pertaining to class II of the
Biopharmaceutical Classification System. The emulsifying
system considerably enhanced the in vitro drug dissolution
extent and rate in comparison with the free drug (20 vs. 3% at
6 h). The formulation clearly improved the in vitro activity of
the drug against the intracellular stage of T. cruzi. Cruz-Bustos
et al. (2012) used Quillaja saponin (an immunostimulant agent
used as vaccine adjuvant, which forms nanometer pentagonal
dodecahedral balls known as immunostimulant complexes) in
the design of targeted nanocapsules loaded with actinomycin D
and functionalized with anti–T. cruzi antibodies. Confronted
with T. cruzi epimastigotes, the encapsulated drug elicited
trypanocidal effects in a dose-dependent manner, at much lower
concentrations than the free drug control. Remarkably, this is to
our best knowledge the first reported targeted lipid nanocarrier
against Chagas disease.
De Morais et al. (2019) reported the obtention of polymeric
micelles and phospholipid 2-dipalmitoyl-sn-glycero-3-
phosphocholine liposomes containing the photosensitizer
drug hypericin. The mean size, polydispersity index, or
zeta potential were not informed. Confronted with T. cruzi
trypomastigotes, pluronic micelles showed efficacious even in
the absence of light, with their EC50 around 7 µmol L−1. Under
light, the best result was achieved by the liposomal system, with
EC50 around 0.31 µmol L−1. Although free hypericin showed a
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very similar potency, authors underlined that the encapsulated
drug would be protected against blood components, which
constitutes and additional advantage of the loaded liposomes.
At last, Parra et al. (2020) reported the obtention of double
targeted imiquimod-containing nanovesicles prepared from
lipids from the archaebacterium Halorubrum tebenquichense,
to induce protection against T. cruzi infection. The therapeutic
efficacy of the vesicles was assessed in a mice model of acute
infection, and it was shown that it prevented mortality, reduced
parasitemia levels (although not as much as benznidazole), and
reduced myocardial and skeletal muscle damage (even more
than benznidazole).
Violacein, a natural colorant produced by some Gram-
negative bacteria, showed a predominantly apoptotic effect in
developmental forms of T. cruzi (Y strain) and selectivity
index of 9 (Canuto et al., 2019). However, the poor aqueous
solubility of violacein is a serious obstacle for development
pharmaceutical formulations. In the present year, Rivero Berti
et al. (2020) developed a novel SLN formulation of violacein
containing surface-active ionic liquids (SAILs) of the cation 1-
alkylimidazolium and a fluorescent tracer DiOC18. The results
indicate 6-fold incorporation of the SLN in mammalian cell
cultures with high apoptotic activity (Rivero Berti et al., 2020).
LEISHMANIASIS
Leishmaniasis is caused by more than 20 different species of
the Leishmania genre, and it is spread to mammalians through
the bite of female phlebotomine infected sandflies. The disease
presents itself in three forms (mainly): cutaneous (the most
common), visceral (the most severe form, also known as kala-
azar), and mucocutaneous. The epidemiology of leishmaniasis
involves many aspects such as type of sandfly species, parasite,
ecological features of the transmission places, and human
behavior (World Health Organization, 2020c,d).
Leishmaniasis Treatment
Alike the already described HAT treatment scenario, there
is a wide range of treatments that may or may not be
applicable, depending on the cost, stage of the disease, parasite
species, geographic location, and tolerability. It is difficult
to develop a single drug capable of universally treating the
disease, because of the huge variability of strains and clinical
manifestations. According to the report of a meeting of the
WHO Expert Committee on the Control of Leishmaniases,
the recommended drugs are amphotericin B (traditional and
liposomal formulation), pentavalent antimonial, paromomycin,
miltefosine, and pentamidine.
Amphotericin B (AmBD) is an aminoglycoside with biostatic
or biocidal properties that binds to sterols (ergosterol) in the cell
membrane of microorganisms, thus creating a transmembrane
channel and disrupting the membrane integrity (Wortmann
et al., 2010). Its disadvantages include cost, the route of
administration (slow intravenous infusion), and systemic and
renal toxicity (Stone et al., 2016). In 1997, a liposomal
formulation of AmBD—LAMBD—was authorized by the Food
and Drug Administration (FDA). LAMBD diminishes the
incidence of the severe side effects, thus improving tolerability.
However, the production cost of the liposomal formulation is still
a key barrier to accessibility in endemic countries.
Pentavalent antimonials, mainly meglumine antimoniate
and sodium stibogluconate, are the first-line drugs to treat
leishmaniasis (Frézard et al., 2009; Miranda-Verastegui et al.,
2009). They have been the treatment of choice since 1940. It
has been proposed that sodium stibogluconate may act as a
prodrug that is later reduced in vivo, disrupting the cell thiol
redox potential. It was also shown that these compounds bind
to DNA I topoisomerase inhibiting plasmid DNA unwinding.
Among their many side effects are nausea, vomiting, skin rashes,
abdominal colic, and cardiotoxicity (Frézard et al., 2009). After all
those years as the main clinical choice, the alarming growing rate
of antimonial resistance is not surprising (Arevalo et al., 2001).
Discovered in 1950, paromomycin is an aminoglycoside
antibiotic originally isolated from Streptomyces rimosus
(Wiwanitkit, 2012). It binds to 16S rRNA and consequently
inhibits protein synthesis by increasing the error rate in the
translation process. It also disrupts the pathogen membrane
fluidity and lipid metabolism. In 2006, paromomycin was
approved by the FDA as an antileishmanial medication against
the visceral presentation of the disease. Although it produces
several undesirable side effects such as abdominal cramps and
diarrhea (Wiwanitkit, 2012), it is still considered as one of the
most cost-effective treatments. It is still considered as one of the
most cost-effective treatments. The combination of puromycin
with sodium stibogluconate (SSG&PM) has been demonstrated
safe and effective, with the advantages of being a shorter and less
expensive treatment. SSG&PM has been recommended byWHO
as first-line treatment for visceral leishmaniasis (Kimutai et al.,
2017; Drugs for Neglected Diseases initiative, 2020i).
The alkyl phospholipid miltefosine was the first oral drug
registered to treat visceral leishmaniasis. Itsmechanism of actions
is not still fully understood but it is related to programmed
cell death triggered by alkyl phospholipids. Miltefosine was first
considered as potential treatment in breast cancer and other
solid tumors, but it was discontinued after signs of severe
gastrointestinal toxicity (Sundar and Olliaro, 2007). Later, it
demonstrated high efficacy against Leishmania both in vitro and
in vivo (Croft et al., 1987). In 2014, it was approved as the first
oral treatment of leishmaniasis by the FDA. Its disadvantages
include the already mentioned gastrointestinal toxicity, hand
in hand with high cost and teratogenicity potential (Soto and
Soto, 2006). It did not take long to show the synergy effects in
vitro between miltefosine and liposomal amphotericin B (Seifert
and Croft, 2006). Moreover, a retrospective study demonstrated
a good cure rate (>80%) in human immunodeficiency virus
patients coinfected with visceral leishmaniasis treated with that
combination (Abongomera et al., 2018; Drugs for Neglected
Diseases initiative, 2020a). Currently in the recruiting phase
(phase III), this is a randomized study to test the effectiveness
of oral miltefosine in combination with intravenous liposomal
amphotericin and intramuscular paromomycin in patients with
post Kala Azar dermal leishmaniasis (PKDL) (ClinicalTrials.gov
NCT03399955, 2020; Drugs for Neglected Diseases initiative,
2020g,h). The combination of miltefosine with paromomycin
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was found successful over the intracellular amastigote stage and
in diminishing parasite loads in the liver, spleen, and bone
marrow of an in vivo model (Hendrickx et al., 2017). In 2017,
a randomized trial (phase III) was developed to compare the
effect of miltefosine in combination with paromomycin for
the treatment of visceral leishmaniasis in adults and children
(ClinicalTrials.gov NCT03129646, 2020; Drugs for Neglected
Diseases initiative, 2020g). Results of the study are expected by
the end of 2020.
Pentamidine isethionate has already been discussed for
the treatment of HAT. Pentamidine is a broad-spectrum
anti-infective agent active against several parasitic worms,
protozoa, and fungi with relatively toxic effects, thus requiring
careful monitoring during therapy (Hafiz and Kyriakopoulos
Pentamidine, 2020; World Health Organization, 2020d). It has
been used as monotherapy or in combination to treat cutaneous
and visceral leishmaniasis. However, the adverse effects of the
drug are severe, and consequently, it is preferably averted.
There are some new chemical entities that are undergoing
clinical studies (phase I). DNDI-0690 is a nitroimidazole that
displays very promising (in vitro) activity against laboratory
strains of Leishmania infantum and in vivo in the early
curative hamster model (Van den Kerkhof et al., 2018).
Furthermore, based on in vivo bioluminescence imaging, only
two administrations of this compound were enough to lower
the Leishmania mexicana parasite load by 100-fold in a murine
model of cutaneous leishmaniasis (Wijnant et al., 2019). In
2015, DNDi-0690 was nominated as a preclinical candidate,
intended to be used as oral treatment for visceral and cutaneous
leishmaniasis. Last year, the first trial in humans was started to
evaluate the safety and tolerability of a single administration of
this compound (ClinicalTrials.gov NCT03929016, 2020).
Other compound under phase I is the DNDI-6148, from the
oxaborole class (Drugs for Neglected Diseases initiative, 2020d).
At the preclinical phase, it proved highly active against many
Leishmania species known to produce both visceral (Van den
Kerkhof et al., 2018) and cutaneous leishmaniasis (Van Bocxlaer
et al., 2019). In 2018, a phase I, blinded, randomized, single-dose
trial was started to study the pharmacokinetics and tolerability
of a single oral dose of DNDI-6148 in healthy male subjects
(ISRCTN registry, 2020). The publication of the study results are
expected in 2020.
The association between the University of Dundee,
GlaxoSmithKline (GSK) and DNDi led to identification of
GSK3186899/DDD853651 and GSK3494245/DDD1305143 as
potential candidates to treat visceral leishmaniasis (Drugs for
Neglected Diseases initiative, 2020f). Both compounds show
a favorable pharmacokinetic profile and similar activity to
the frontline drug miltefosine in animal models of visceral
leishmaniasis (Wyllie et al., 2018, 2019; Thomas et al., 2019).
In vitro studies indicate that GSK3186899/DDD853651 main
mechanism can be attributed to the inhibition of the cdc-
2-related kinase 12 (CRK12) of the parasite (Wyllie et al.,
2018). Further studies confirmed that GSK3494245 inhibit
the chymotrypsin-like activity in the Leishmania donovani
proteasome (Wyllie et al., 2019). In 2019, GSK3186899 entered
a double-blind study started to assess its safety, tolerability, and
pharmacokinetic profile in healthy humans (ClinicalTrial.gov
NCT03874234, 2020), but the study was recently suspended by
GSK. By the end of this year, a phase I trial will be developed to
assess the efficacy and safety of GSK3494245 (ClinicalTrials.gov
NCT04504435, 2020).
Novartis and the University of Dundee have reported a
selective proteasome inhibitor with efficacy in murine models
of visceral and cutaneous leishmaniasis, LXE408 (Nagle et al.,
2020), which is currently undergoing phase I human clinical trials
(Drugs for Neglected Diseases initiative, 2020b).
Table 3 summarizes the current therapeutic options for




Leishmaniasis is so far the trypanosomatid-caused condition
that has received more attention in the field of pharmaceutical
lipid nanocarriers, probably due to the facts that one of the
approved drugs against leishmaniasis (amphotericin B) is already
available in liposomal formulation, and what is more, cutaneous
leishmaniasis may at least be partially treated with topical
medications. On the other hand, the predominant role of
macrophages in the sequestration of circulating nanocarriers
(Baboci et al., 2020) coupled with their importance on
Leishmania infection establishment and the persistence of the
parasite inside the host (De Menezes et al., 2017; Soulat and
Bogdan, 2017; Holzmuller et al., 2018) may have contributed
to the development of drug nanodelivery systems for this
disease. Predictably, then, a substantial fraction of the reported
nanosystems correspond to amphotericin B drug delivery
systems. Noteworthy, leishmaniasis is also the trypanosomatid-
caused infection for which the widest diversity of lipid
nanocarriers has been investigated.
Because macrophages play a crucial role in leishmaniasis
(they take part of the immune response against the parasite,
but they also constitute the final host cells for its proliferation)
(Tomiotto-Pellissier et al., 2018), many researchers have designed
macrophage-directed antileishmanial drug delivery systems.
Gupta et al. (2007) formulated amphotericin B in trilaurin
emulsomes stabilized by soy phosphatidylcholine and targeted
with O-palmitoyl mannan, a macrophage-specific ligand. The
antileishmanial performance was tested. The antileishmanial
activity was tested both in vitro and in vivo, demonstrating
that the decorated emulsomes outperformed both non-decorated
drug-loaded emulsomes and the free drug. Similar results were
later observed in mice by Veerareddy et al. (2009) using
mannose-decorated lipid nanospheres, comparing their efficacy
with Fungizone. The decorated nanosystem achieved better
performance than Fungizone or the non-decorated formulation.
Additionally, mice treated with the encapsulated drug show
no elevation in serum glutamate pyruvate transaminase,
alkaline phosphatase, urea, and creatinine levels and increased
bioavailability in comparison with Fungizone. Remarkably, the
targeted system was found to distribute more rapidly to the liver
and the spleen. Rathore et al. (2011) proposed a formulation of





































TABLE 3 | The therapeutic scenario for leishmaniasis, including WHO-recommended drugs, and current clinical trials.
Drugs Stage of the disease Administration via Adverse reactions References
Drugs used to treat cutaneous and visceral leishmaniasis recommended by WHO
Amphotericin B, AmBD and liposomal
amphotericin B, amphotericin B lipid complex,
and amphotericin B colloidal dispersion
Visceral leishmaniasis IV Nephrotoxicity, also myocarditis and death. The liposomal, lipid and
colloidal formulations show fewer side effects (rigors and chills)
(Freitas-Junior et al., 2012; ClinicalTrials.gov
NCT0265679, 2020; World Health Organization,
2020d)
Pentavalent antimonials meglumine





Common side effects are anorexia, vomiting, nausea, abdominal pain,
malaise, myalgia, arthralgia, headache, metallic taste and lethargy.
High cardiotoxicity, pancreatitis, nephrotoxicity, hepatotoxicity; high
treatment failure (up to 65% in major epidemic areas)









Gastrointestinal symptoms including nausea, vomiting, diarrhea, and
abdominal discomfort. Nephrotoxicity and ototoxicity are rarely
produced
(Ben Salah et al., 2013; ClinicalTrials.gov
NCT01140191, 2020; World Health Organization,
2020d)
Miltefosine Visceral and cutaneous
leishmaniasis
Oral Gastrointestinal symptoms, nephrotoxicity, hepatotoxicity,
teratogenicity
(Dorlo et al., 2012; ClinicalTrials.gov
NCT03129646, 2020; World Health Organization,
2020d)




Diabetes mellitus, severe hypoglycemia, shock, myocarditis, and
renal toxicity; limit its use

























































































TABLE 3 | Continued
Drugs Stage of the disease Administration via Adverse reactions References
Undergoing clinical trials
Miltefosine + liposomal amphotericin B +
paromomycin







Not reported yet (ClinicalTrials.gov NCT03399955, 2020; Drugs for
Neglected Diseases initiative, 2020g)
Miltefosine + paromomycin Visceral leishmaniasis Oral Not reported yet (ClinicalTrials.gov NCT03129646, 2020)
Miltefosine + paromomycin Cutaneous leishmaniasis Oral (miltefosine) Topical
(paromomycin)
(ClinicalTrials.gov NCT03829917, 2020)
DNDI-0690 Visceral and cutaneous
leishmaniasis
Oral Not reported yet (ClinicalTrials.gov NCT03929016, 2020)
DNDI-6148 Visceral and cutaneous
leishmaniasis
Oral Not reported yet (ISRCTN registry, 2020)
GSK3186899/DDD853651 (suspended) Visceral leishmaniasis Oral Not reported yet (ClinicalTrials.gov NCT03874234, 2020)
GSK3494245/DDD1305143 Visceral leishmaniasis Oral Not reported yet ClinicalTrials.gov Identifier: NCT04504435
Visceral and cutaneous
leishmaniasis
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amphotericin B mannosylated liposomes for the active targeting
to the reticular endothelial system. They compared the drug
release and biodistribution (in a hamster model of infection)
of the free drug, undecorated liposomes, and mannosylated
liposomes. At 24 h, comparable but slightly lower percentage of
drug release were observed for mannose-coupled liposomes, an
expected behavior having in mind the additional diffusional layer
present in the decorated carriers. The mannosylated formulation
displayed the highest reduction in parasite load, and it was
confirmed that the active targeting strategy led to a comparative
reduction of circulating liposomes with the concomitant rise in
drug increase in liver and spleen. Mannosylated nanomicelles
have also been proposed to deliver combination therapy of
amphotericin B and doxorubicin for visceral leishmaniasis (Wei
et al., 2020).
Using nanoprecipitation followed by sonication, Patel and
Patravale (2011) obtained amphotericin B SLN conceived
for oral administration (AmbiOnp). The effects of several
processes (probe sonication, dialysis cycles, freeze drying,
and reconstitution) on the physicochemical features of the
nanoparticles (such as particle size, dispersion and entrapment
efficiency) were examined. Untreated SLN displayed a relatively
high mean diameter (about 350 nm) and considerable dispersion;
both were substantially reduced by sonication and dialysis.
Drug loading significantly increased the mean diameter of
the SLN. A single-dose acute toxicity study suggested the
(acute) safety of AmbiOnp orally. Pharmacokinetic studies
in rat using a non-compartmental approach suggested and
enhanced relative bioavailability of AmbiOnp in comparison to
a free drug solution (including a substantial increment in the
elimination half-life, the time to reach the concentration peak
in plasma, and the total area under the plasma concentration–
time curve), although additional time points in the terminal
phase of the concentration–time curve should have been
obtained for a more accurate estimation of most of the
estimated pharmacokinetic parameters. A subsequent study with
the same formulation and an improved sampling schedule
confirmed, however, that oral AmbiOnp presented increased
half-life and total area under the concentration–time curve
in comparison to intravenous Fungizone (Chaudhari et al.,
2016).
Singodia et al. (2011) reported the obtention of alginate-
coated amphotericin B–loaded lipid nanoparticles, hypothesizing
that activation of macrophages by alginate would synergize the
antileishmanial effects of the drug. The lipid nanoparticles
without coating presented a mean particle size of 108 nm,
whereas alginate coating increased the mean size to 134 nm
and reversed the zeta potential from +28.4 to −19.8mV.
Moderate entrapment efficiency was observed. Inhibition
of intramacrophage amastigotes was significantly higher
compared to non-coated drug-loaded lipid nanoparticles. Very
similar results were documented by Jain et al. (2014) who
prepared chitosan-coated SLN loaded with amphotericin B
for immunoadjuvant chemotherapy of leishmaniasis. Besides
enhanced efficacy in comparison to Fungizone and AmBisome,
the authors demonstrated the improved safety profile of the
developed formulation in acute toxicity studies.
Lipid–polymer antileishmanial hybrid nanoparticles were
designed by Asthana et al. (2015) composed of a poly(D,L-
lactide-co-glycolide) core and a stearylamine shell and loaded
with amphotericin B. Stearylamine was selected as the lipid
component because of its immunostimulant activity and because
it acts as a ligand for stearylamine pattern recognition receptors
present on the macrophage surface. The stearylamine shell
increased the size of the nanoparticles and reverted their charge
from negative to positive. The particles used for subsequent
studies were about 175 nm. The reported system displayed a
very attractive profile, including sustained drug release, reduced
erythrocyte and macrophage toxicity, enhanced macrophage
uptake, higher accumulation in the spleen and the liver, minima
distribution in kidneys, considerable antileishmanial efficacy
in vitro and in vivo against visceral leishmaniasis, and low
levels of nephrotoxicity markers. The authors indicated that
macrophage pattern recognition receptors were involved in the
uptake of the nanoparticles and that the positive charge of
the lipid shell allows them to bind to the negatively charged
macrophage surface, favoring adsorption mediated endocytosis.
Another recently reported hybrid system loaded with both
amphotericin B and paromomycin consisted of SLN modified
with 2-hydroxypropyl-β-cyclodextrin as an oral matrix system
against visceral leishmaniasis (Parvez et al., 2020). The reported
formulation possesses a sustained drug release profile. In vitro
studies verified the total cellular internalization of the modified
SLNs with low cytotoxicity in macrophage cells within 24 h
of incubation. Moreover, the nanosystem did not elicit hepatic
or renal toxicity in mice. In vitro and in vivo studies showed
improved efficacy on L. donovani intracellular amastigotes and
significantly reduced the liver parasite burden in comparison
to miltefosine.
A very interesting, novel approach for the targeted delivery
of amphotericin B was devised by Kumar and Bose (2019),
who implemented a “ghost cell” (nanoghost) strategy utilizing
macrophage membrane-derived nanovesicles as a specific
carrier for the drug. The nanoghost delivered the drug
specifically to infected macrophages driven by antigenic
identification of infected tissues associated to low toxicity toward
healthy cells.
Less frequently, other approved drugs against leishmaniasis,
besides amphotericin B, have been formulated in colloidal lipid
systems. For instance, paromomycin SLN with good entrapment
efficiency was reported by Ghadiri et al. (2011). Sometime
later, Gaspar et al. (2015) reported the development of six
paromomycin liposomal formulations whose biodistribution
profiles revealed preferential targeting of the antibiotic to the
spleen, liver, and lungs, relative to the free drug. Such observation
translated into an augmented therapeutic effect inmurinemodels
of infection with L. infantum and improved safety profile.
Positive results were also observed by Heidari-Kharaji et al.
(2016), who prepared paromomycin-loaded SLN and tested their
efficacy in vivo against L. major–infected mice. The parasite load
in the footpad swelling was analyzed by real-time PCR, and the
level of cytokines was also assessed. The study showed that the
developed formulation was efficacious in killing the parasite and
switching toward TH1 response.
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da Gama Bitencourt reported the obtention of miltefosine-
loaded lipid nanoparticles that enhanced the drug stability with
reduced cytotoxicity in macrophages and diminished hemolytic
potential, but also retaining the antiparasitic activity (da Gama
Bitencourt et al., 2016). Interestingly, because of the amphiphilic
nature of the drug, it acted as a powerful surfactant, and addition
of increasing amounts of miltefosine reduced the mean particle
size, from 144 nm (unloaded nanoparticles) to 40 to 65 nm.
Moosavian et al. (2019) obtained meglumine antimoniate-
loaded liposomes containing stearylamine. Liposomal
formulations enhanced the drug permeation compared with
meglumine antimoniate cream. The liposomal formulation
containing stearylamine proved more efficacious than drug-
loaded liposomes without stearylamine. In a mice model of
cutaneous leishmaniasis, liposomal groups presented smaller
lesions compared to control.
Lipid Nanosystems Encapsulating
Non-approved Drugs
Lopes et al. (2012) obtained tripalmitin SLN encapsulating
the potential antileishmanial dinitroaniline oryzalin. The
nanoparticles were stabilized by mixed emulsifier molecules such
as soy lecithin, sodium deoxycholate, and Tween 20. The cell
viability experiments proved that the nanoencapsulation of the
drug diminished its cytotoxicity. A subsequent study by the same
group compared the safety and efficacy of oryzalin-loaded SLN
and liposomes with those of the free drug (Lopes et al., 2014).
As observed in other reviewed articles of the current section,
the nanoformulations revealed diminished cytotoxicity and
hemolytic activity in comparison with the free drug and without
losing in vitro efficacy. Superiority of both nanocarriers on the
reduction of parasitic burden in spleen and liver (compared
with free oryzalin) was demonstrated in a mice model of
visceral leishmaniasis. Kupetz et al. (2013) screened a number
of colloidal systems to develop parental formulations of the
poorly soluble paullon chalcone derivative KuRei300, including
micelles stabilized with lecithin/bile salts, liposomes, supercooled
smectic liquid crystal of cholesterol myristate nanoparticles, a
triglyceride emulsion, and cubic phase nanoparticles.
Other lipid nanosystems have been proposed to exploit the
antileishmanial activity of lipophilic compounds and mixtures
of natural origin. Marquele-Oliveira et al. (2016) reported a
nanodelivery system based on stearic acid SLN encapsulating
the liposoluble lignan fraction of the South American plant
Ocotea duckeiVattimo, which targets the Leishmania lysosome of
macrophages. Physicochemical analysis revealed that the delivery
system presented a core-shell architecture, and the correspondent
dissolution studies revealed that the active components are
released by a matrix diffusion-based kinetic mechanism. The
loaded SLN displayed no toxicity to murine macrophages with
an in vitro antileishmanial effect. Comparable results were
reported by Want et al. (2017), who developed a liposomal
artemisinin formulation. Nanoliposomal artemisinin proved
superior performance compared to free artemisinin in a mice
model of visceral leishmaniasis, withmodulation of cell-mediated
immunity toward protective TH1 type. Similarly, Kar et al.
(2017) prepared NLC loaded with cedrol, one of the major
sesquiterpenes obtained from the genus Cupressus). In vivo
studies revealed that the antileishmanial effects of the orally
administered nanoformulation were increased (in comparison
with free cedrol and miltefosine) against wild type but also
to drug-resistant strains of L. donovani. Sousa-Batista et al.
(2017) reported the obtention of lipid-core nanoparticles made
of capric/caprylic triglyceride, sorbitan monostearate (i.e., Span
60TM), and poly(ε-caprolactone), for the oral delivery of quercetin
and quercetin penta-acetate; the quercetin-loaded nanoparticles
enhanced the oral efficacy of the drug in a model of cutaneous
leishmaniasis (mice). Noteworthy, aspartate aminotransferase,
alanine aminotransferase, or creatinine serum levels were not
modified by the treatments, suggesting they had no liver or
renal toxicity. Das et al. (2017) prepared ursolic acid–loaded
NLC coated with chitosan oligosaccharides for the visceral
leishmaniasis therapy, intended to deliver such active ingredient
to macrophages following oral administration. The formulated
NLC had nano sizes ranging from 104 to 143 nm, with high drug
loading capacity and relatively good entrapment efficiency. The
nanoformulation was highly efficient than the free drug against
cellular amastigotes from a diversity of strains. It could also
substantially suppress the parasite burden in vivo. Very recently,
NLC containing the monoterpene carvacrol (which, despite
promising antileishmanial activity, displays low water solubility,
high volatility, and stability issues) has been described (Galvão
et al., 2020). The highest encapsulation efficiency was achieved
by using beeswax as solid lipid. The drug release from the
NLC fitted to the Korsmeyer and Peppas, and Weibull models,
suggesting a Fickian release mechanism. Carvacrol incorporation
to the NLC resulted in diminished cytotoxicity in comparison
to the free drug, also increasing its in vitro antileishmanial
efficacy (amastigotes). The encapsulation also led to increased
elimination half-life in rats.
Recently, Smith et al. (2018) described high-loading self-
nanoemulsifying systems for the oral delivery of the poorly
soluble antiprotozoal hydroxynaphthoquinone buparvaquone.
This self-emulsifying system showed an improved oral
bioavailability compared to aqueous dispersions, which
translated into an increase area under the plasma concentration–
time curve. It demonstrated potent in vitro efficacy, and it almost
completely suppressed parasite replication in the spleen, whereas
it also inhibited the parasite replication in the liver. Mazur et al.
(2019) devised beeswax nanoparticles containing copaiba oil to
encapsulate diethyldithiocarbamate, which has previously shown
excellent leishmanicidal effect. The nanoformulation decreased
the cytotoxic effects of the drug against macrophages, which led
to an almost 2-fold increase in the selectivity index.
CONCLUSIONS
The reviewed literature shows that the state of the art of lipid
nanodelivery systems in the field of human trypanosomatid-
caused diseases greatly varies, depending on the disease. Limited
efforts have still been made in relation to drug nanocarriers
for HAT or Chagas. In the case of HAT, the limited interest in
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pharmaceutical nanocarriers possibly responds to the favorable
evolution of the epidemiological data in the last decade and the
incorporation of novel, efficacious, convenient, and bioavailable
options to the therapeutic arsenal. Regarding Chagas disease,
there are still not enough or convincing data that suggest that the
use of nanodevices could help overcoming the limitations of the
currently (and extremely limited) available medications. In any
case, the reviewed articles show that most of the reported lipid
nanosystems for HAT or Chagas correspond to delivery systems
from previous generations (prominently, non-targeted liposomes
and SLN). In other words, the potential contribution of state-of-
the-art lipid nanocarriers, including functionalized and hybrid
systems, has still to be explored. The most relevant challenges
here might be the delivery of effective levels of the drugs to
poorly irrigated/accessible tissues, targeted delivery to the most
affected organs (which could contribute to improved safety and
tolerability), and the enhanced effect on dormant parasites.
The scenario is substantially different in the case of
leishmaniasis, where a large variety of lipid systems with
distinctive architectures and functionalities have been
successfully tested at the preclinical level, including macrophage-
targeted systems with enhanced parasiticidal effects in affected
organs such as liver or spleen and immunostimulant hybrid
systems. Either nanoencapsulating already approved or
experimental drugs, the outcome of those studies with a focus on
lipid nanosystems consistently includes sustained drug release,
reduced cytotoxicity and liver and renal toxicity, increased safety
and efficacy, and improved bioavailability.
Multiple factors can possibly explain the different
scenarios described across diseases, including historical and
pathophysiological aspects. Colloidal drug delivery systems
(liposomal amphotericin B) are already available to treat
leishmaniasis. The disease includes cutaneous presentations that
can be treated systemically, but also in combination with topical
formulations. Particularly, the macrophages have a relevant
role in the establishment and evolution of the infection, and
as we know, they are likely to be targeted by pharmaceutical
nanocarriers. A considerable proportion of the studies linked to
lipid systems in leishmaniasis focus on the oral delivery of poorly
soluble/poorly bioavailable drugs, which includes a diversity of
lipophilic natural products. Lipid nanocarriers thus constitute
a valid alternative to exploit the rich chemical biodiversity and
expand the therapeutic options for neglected conditions.
Besides their already discussed advantages (e.g.,
biocompatibility and biodegradability), other possible reasons
might explain the relative abundance of studies linked to
the development of lipid nanocarriers for the treatment
of trypanosomatid-caused conditions. Among them is the
suitability of these delivery systems to load comparatively high
amounts of lipophilic agents. It should be considered that, in the
case of parasitic diseases, the therapeutic agents must often access
to the parasite intracellular space. Furthermore, some parasite
reservoirs might be found in deep tissues (poorly irrigated tissues
such as adipose tissue or tissues separated from circulation
by specialized barriers, e.g., the brain). In any case, lipophilic
chemotherapies would be often required to provide an extensive
drug distribution and circumvent the correspondent biological
barriers. These facts explain why many therapeutic agents for
parasitic diseases do display a significant lipophilicity (in fact,
they are one of the therapeutic categories whose members often
violate Lipinski rules).
The route of administration and the costs are almost
key factors when formulating active ingredients, but that is
especially true when dealing with therapeutics for neglected
conditions, as the convenience of the dosing forms and the
cost of the therapeutic intervention are particularly relevant.
Enhancing the efficacy–safety balance of already known drugs
by encapsulating themwithin state-of-the-art nanovehicles could
provide affordable solutions for the treatment of neglected
conditions. Furthermore, the recent reports on quiescent
or dormant stages of the parasite that cause the (today)
most challenging human trypanosomatid-caused disorders
(leishmaniasis and Chagas disease) may at least partially explain
drug failure. It has been suggested that therapeutic benefits might
thus be achieved with extended treatments; if so, pharmaceutical
carriers enhancing tolerability could be more advantageous than
ever. All things considered, improved safety could contribute
to treatment adherence (a fundamental aspect in the field of
infectious diseases, both from individual and public health
perspective) and to the design of well-tolerated extensive
dosing plans.
Despite its continuous and vertiginous progress,
nanobiotechnology is still an emerging field, and many
technological and regulatory challenges are to be faced before
massive adoption within the pharmaceutical industry. Individual
and environmental toxicological aspects and accurate and
standardized evaluation of their pharmacokinetic profile are also
to be solved. Lipid-based systems, because of their biocompatible
nature, appear as a reasonable option to address some of these
issues, whereas stability and scaling-up cost are possibly among
their major disadvantages.
Finally, we would like to underline the need to explore
last-generation pharmaceutical nanocarriers as vehicles for the
treatment of trypanosomatid-caused diseases, disorders that in
most cases have been only addressed preclinically using early
generations of lipid-based systems. Unfortunately, for the time
being, the development of therapeutic options involving last-
generation technologies possibly collides with the necessity to
achieve affordable solutions for neglected conditions.
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